$77.1 Million is the total value of Polaris Venture Management Co. V, L.L.C.'s 8 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
FATE | Fate Therapeutics, Inc. | $46,987,000 | -9.3% | 569,889 | 0.0% | 60.92% | -9.9% | |
LYRA | Lyra Therapeutics, Inc. | $12,759,000 | +1.7% | 1,100,852 | 0.0% | 16.54% | +1.0% | |
SELB | Selecta Biosciences, Inc. | $12,550,000 | +49.3% | 2,773,479 | 0.0% | 16.27% | +48.4% | |
XFOR | x4 Pharmaceuticals Inc. | $2,682,000 | +33.9% | 311,492 | 0.0% | 3.48% | +33.1% | |
LIFE | Atyr Pharma Inc. | $581,000 | +14.6% | 130,572 | 0.0% | 0.75% | +13.7% | |
DARE | Dare Bioscience, Inc. | $551,000 | +26.1% | 326,241 | 0.0% | 0.71% | +25.3% | |
GNCA | Genocea Biosciences, Inc. | $535,000 | +11.9% | 197,345 | 0.0% | 0.69% | +11.2% | |
PULM | Pulmatrix, Inc. | $478,000 | +11.7% | 359,441 | 0.0% | 0.62% | +10.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-12
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
Fate Therapeutics, Inc. | 30 | Q2 2021 | 79.2% |
Atyr Pharma Inc. | 26 | Q3 2021 | 15.1% |
Trevena, Inc. | 22 | Q2 2019 | 24.9% |
Genocea Biosciences, Inc. | 21 | Q1 2019 | 32.5% |
Selecta Biosciences, Inc. | 20 | Q1 2021 | 39.5% |
T2 Biosystems, Inc. | 20 | Q2 2019 | 36.1% |
Dare Bioscience, Inc. | 17 | Q3 2021 | 3.9% |
Pulmatrix, Inc. | 16 | Q1 2019 | 15.4% |
Cerulean Pharma Inc | 13 | Q2 2017 | 16.2% |
Kala Pharmaceuticals, Inc. | 11 | Q1 2020 | 37.1% |
View Polaris Venture Management Co. V, L.L.C.'s complete holdings history.
Latest filings
Type | Filed |
---|---|
3 | 2022-03-30 |
13F-HR | 2021-11-12 |
13F-HR | 2021-08-12 |
13F-HR | 2021-05-12 |
13F-HR | 2021-02-12 |
13F-HR | 2020-11-12 |
13F-HR | 2020-08-12 |
13F-HR | 2020-05-14 |
4 | 2020-05-06 |
3 | 2020-04-30 |
View Polaris Venture Management Co. V, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.